Loading…
← CockpitCompetitor Analysis › 041960.KS Komipharm International Co., LtdOpen in the cockpit ↗

Komipharm International Co., Ltd041960.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology
Momentum strong 76
Mkt cap
$454M
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$1.31M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.8 pp
WACC 5.5%
Hurdle
n/a
no reverse DCF
Close · KRW₩8,470
1D+1.7%
1W-3.6%
1M-13.7%
3M-7.9%
6M-1.9%
YTD+20.7%
1Y+42.1%
ATR %5.7%
52w lowhigh28.8% off high

What Komipharm International does

Employees: 172

Komipharm International at a glance

Size Komipharm International (041960.KS) is a South Korea Health Care company (Biotechnology) with a market value of $454M, the 368th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩8,470 on 18 Nov 2026.

Performance Over six months the shares fell 1.9%, against -6.3% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th highest of 19 in its peer set.

Growth Revenue fell 6.5% over the last twelve months (peer median +4.9%); the operating margin is -0.8% (peer median -17.2%).

Valuation It trades at 11.8× enterprise value to sales against a peer median of 6.4× (6th most expensive of 14).

Capital Return on invested capital runs 5.8 points below its cost of capital (5.5% WACC).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026041960.KS 104Peer median 95
Six months, rebased to 100: Komipharm International against the median of its 20 peers (local-currency closes).

Komipharm International financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩52.7B₩52.5B₩58.8B₩42.6B₩39.8B
Revenue growth—-11%+38%+7%—
Gross profit₩17.2B₩15.9B₩20.4B₩11.0B₩9.55B
EBITDA₩2.09B₩2.92B₩8.37B-₩2.74B-₩438M
Net income-₩6.75B-₩7.21B₩13.1B-₩3.98B-₩6.51B
Free cash flow-₩5.20B-₩3.71B₩7.80B-₩3.44B-₩2.66B
Capital expenditure₩3.82B₩4.47B₩3.98B₩1.13B₩1.07B
Total debt₩39.3B₩40.7B₩43.8B₩45.1B₩38.1B

Quarterly statements and history in the cockpit →

Komipharm International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%STTK115180DMAC6589KMDAARVNIRLA000710FENC6037391789414725096712041960.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Komipharm International is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×25×50×75×1151806589KMDA000710FENC4147PRTA25096712041960.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Komipharm International is the large dot.

Komipharm International competitors and peer comparison

How Komipharm International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Komipharm International against its 20 peers (data as of 18 Nov 2026)
Measure041960.KSPeer medianRank in peer set
1-month return-13.7%-5.4%6th lowest of 21
6-month return-1.9%-6.3%10th highest of 19
Distance from 52-week high-28.8%-39.7%6th highest of 21
Revenue growth (TTM)-6.5%+4.9%5th lowest of 15
Operating margin-0.8%-17.2%6th highest of 15
EV / Sales11.8×6.4×6th most expensive of 14
ROIC minus cost of capital-5.8 pp-8.6 pp5th highest of 11
Net debt / EBITDA8.1×-3.4×most indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%

Questions

Which companies are Komipharm International's closest peers?
The cockpit's peer set: Shattuck Labs (STTK), Qurient (115180.KS), HanchorBio (7827.TW), DiaMedica Therapeutics (DMAC), EirGenix (6589.TW), Kamada (KMDA), Arvinas (ARVN), IRulya Therapeutics (IRLA).
Is Komipharm International expensive compared with its peers?
On ev / sales it trades at 11.8× against a peer median of 6.4×, 6th most expensive of 14 in its peer set.
How has Komipharm International stock performed?
Over six months to 18 Nov 2026 the shares returned -1.9% against -6.3% for the median peer; over one year +42.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.